Since the most frequent or highly expanding TCR clones might be tumor-recognizing T cells (20), DP treatment displayed superior ability to mediate the expansion of potential cancer-specific clonal progenitor Tex compared with anti–PD-1 or decitabine single-agent therapy. Here, PDCD1 is linked to cancer.